EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-World Impact of UGT1A1 Genotype–Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study

Niels Heersche, Sofía L J Peeters, Doortje Böhm, Stefan Böhringer, Roselien Guiljam, Emma C Hulshof, Femke M de Man, Mirjam de With, Marije Joosse, Gysella Oomens, Qiong-Yi Wu, Sander Bins und 10 weitere

Journal of the National Comprehensive Cancer Network · 2026

DOI: 10.6004/jnccn.2026.7011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Niels Heersche und 21 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Irinotecan, Glucuronosyltransferase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risk of irinotecan-related severe toxicity is significantly higher in patients carrying 2 dysfunctional UGT1A1 gene variants, characterized as poor metabolizers (PMs), following standard irinotecan dosing. Since 2020, we implemented UGT1A1 genotype–guided dosing of irinotecan in routine clinical practice to reduce toxicity in PMs. This study evaluates its impact on severe toxicity in a real-world cohort. Patients and Methods: Our study cohort included adult patients who received UGT1A1 genotype–guided irinotecan dosing at 6 Dutch hospitals between December 2020 and April 2024. Patients were included in the primary analysis if irinotecan was dosed according to UGT1A1 genotype (ie, 100% ±10% dose intensity for intermediate and normal metabolizers [IM/NMs] and 70% ±10% for PMs) in at least cycle 1. Toxicities, hospitalizations, and treatment alterations were collected for cycles 1–3 and graded according to CTCAE version 5.0. Endpoints were compared between PMs with a 70% starting dose and fully dosed IM/NMs.

Results

A total of 501 patients were included in the primary analysis; 54 of whom were PMs (10.8%). Baseline characteristics were evenly distributed between groups. The incidences of overall severe toxicity (29.6% vs 34.0%; P =.52), febrile neutropenia (3.7% vs 5.8%; P =.76), severe neutropenia (17.0% vs 17.8%; P =.88), severe diarrhea (13.0% vs 15.0%; P =.69), and toxicity-related hospitalization (14.8% vs 21.7%; P =.24) were comparable between dose-reduced PMs and fully dosed IM/NMs. In a secondary analysis, 9 UGT1A1 PMs who received an unintended full irinotecan dose experienced more severe toxicity than PMs with a 70% starting dose (overall severe toxicity: 77.8% vs 29.6%; P =.009).

Conclusions

UGT1A1 genotype–guided dosing of irinotecan improves patient safety and treatment tolerability of irinotecan. A 70% starting dose of irinotecan for UGT1A1 PMs is necessary to normalize the risk of severe toxicity to that of IM/NMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanGlucuronosyltransferaseHumansUGT1A1 EnzymeFemaleMiddle AgedMaleGenotypeAgedHospitalizationAdult

Substanzen

IrinotecanUGT1A1 EnzymeGlucuronosyltransferase

Autor:innen und Institutionen

  • 1Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • 2Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • 3Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.
  • 4Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
  • 5Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
  • 6Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.

Zitieren

APA

Heersche, N., Peeters, S. L. J., Böhm, D., Böhringer, S., Guiljam, R., Hulshof, E. C., de Man, F. M., de With, M., Joosse, M., Oomens, G., Wu, Q. Y., Bins, S., van Hellemond, I. E. G., Haberkorn, B. C. M., Verschoor, A. J., Wumkes, M. L., Thijs, A. M., van Schaik, R. H. N., Gelderblom, H., …, & Deenen, M. J. (2026). Real-World Impact of UGT1A1 Genotype–Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7011

Vancouver

Heersche N, Peeters SLJ, Böhm D, Böhringer S, Guiljam R, Hulshof EC, et al. Real-World Impact of UGT1A1 Genotype–Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2026.7011

BibTeX
@article{Heersche2026,
  author = {Heersche, Niels and Peeters, Sofía L J and Böhm, Doortje and Böhringer, Stefan and Guiljam, Roselien and Hulshof, Emma C and de Man, Femke M and de With, Mirjam and Joosse, Marije and Oomens, Gysella and Wu, Qiong-Yi and Bins, Sander and van Hellemond, Irene E G and Haberkorn, Brigitte C M and Verschoor, Arjan J and Wumkes, Miriam L and Thijs, Anna M and van Schaik, Ron H N and Gelderblom, Hans and Guchelaar, Henk-Jan and Mathijssen, Ron H J and Deenen, Maarten J},
  title = {Real-World Impact of UGT1A1 Genotype–Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  doi = {10.6004/jnccn.2026.7011}
}
Kostenlos starten →